Index -
P/E -
EPS (ttm) -7.19
Insider Own 18.14%
Shs Outstand 2.98M
Perf Week 11.12%
Market Cap 37.13M
Forward P/E -
EPS next Y -2.92
Insider Trans -56.55%
Shs Float 2.12M
Perf Month 5.89%
Income -35.81M
PEG -
EPS next Q -2.17
Inst Own 10.78%
Short Float 15.00%
Perf Quarter 22.47%
Sales 0.00M
P/S -
EPS this Y 72.79%
Inst Trans -70.17%
Short Ratio 2.13
Perf Half Y 12.86%
Book/sh -1.94
P/B -
EPS next Y 34.46%
ROA -144.33%
Short Interest 0.32M
Perf Year 63.15%
Cash/sh 7.12
P/C 2.02
EPS next 5Y -
ROE -946.56%
52W Range 8.44 - 37.00
Perf YTD 23.15%
Dividend Est. -
P/FCF -
EPS past 5Y 8.64%
ROI -
52W High -61.11%
Beta 0.51
Dividend TTM -
Quick Ratio 0.77
Sales past 5Y -40.00%
Gross Margin 84.00%
52W Low 70.40%
ATR (14) 1.48
Dividend Ex-Date -
Current Ratio 0.77
EPS Y/Y TTM -24.91%
Oper. Margin 0.00%
RSI (14) 58.75
Volatility 12.96% 12.88%
Employees 14
Debt/Eq -
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.00
Target Price 73.33
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q -1434.65%
Payout -
Rel Volume 2.34
Prev Close 13.45
Sales Surprise -
EPS Surprise -21.28%
Sales Q/Q -100.00%
Earnings Mar 25 AMC
Avg Volume 149.08K
Price 14.39
SMA20 8.42%
SMA50 20.77%
SMA200 -2.82%
Trades
Volume 348,931
Change 6.99%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-25-22 Downgrade
Stifel
Buy → Hold
$20 → $6.20
Nov-09-21 Upgrade
Stifel
Hold → Buy
$20
Oct-12-21 Initiated
Credit Suisse
Outperform
$20
Oct-04-21 Initiated
Mizuho
Buy
$20
Sep-21-21 Initiated
JMP Securities
Mkt Outperform
$33
Sep-20-21 Initiated
Stifel
Hold
$20
Sep-13-21 Initiated
Cantor Fitzgerald
Overweight
$50
Mar-25-24 09:53PM
04:01PM
Feb-05-24 08:30AM
Jan-30-24 09:55AM
Jan-29-24 04:05PM
08:00AM
Loading…
Jan-25-24 08:00AM
Jan-09-24 08:05AM
08:00AM
Dec-08-23 08:15AM
Nov-28-23 08:00AM
Nov-15-23 08:00AM
Nov-13-23 04:14PM
Nov-06-23 08:00AM
Oct-24-23 08:00AM
Sep-11-23 08:00AM
08:00AM
Loading…
Aug-30-23 08:00AM
Aug-11-23 06:05AM
Aug-08-23 04:01PM
Jun-08-23 04:01PM
Jun-07-23 08:00AM
May-31-23 05:43PM
May-26-23 09:00AM
May-25-23 04:50PM
May-09-23 04:01PM
May-08-23 08:00AM
Apr-26-23 04:01PM
Apr-11-23 08:00AM
Mar-28-23 08:30AM
Mar-08-23 04:01PM
Feb-21-23 08:30AM
08:00AM
Loading…
Jan-30-23 08:00AM
Jan-05-23 04:01PM
Nov-07-22 04:00PM
Oct-31-22 02:05PM
Oct-26-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 09:00AM
Sep-14-22 08:00AM
Sep-06-22 08:30AM
Aug-09-22 04:01PM
Aug-08-22 05:30AM
Jun-07-22 08:00AM
Jun-05-22 05:00PM
May-26-22 05:15PM
May-10-22 04:02PM
May-03-22 06:45AM
May-02-22 04:04PM
Apr-04-22 08:30AM
Mar-16-22 04:01PM
Feb-16-22 08:30AM
Feb-15-22 06:53PM
Feb-09-22 04:00PM
Jan-24-22 04:00PM
Nov-24-21 08:00AM
Nov-22-21 08:00AM
Nov-08-21 07:00AM
Nov-04-21 09:08AM
Nov-01-21 04:05PM
Oct-26-21 08:00AM
Oct-07-21 04:30PM
Sep-30-21 04:32PM
Sep-16-21 08:00AM
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC 10% Owner Nov 27 '23 Sale 0.61 609,163 369,457 1,821,415 Nov 29 05:07 PM WORLAND STEPHEN T Chief Executive Officer Aug 11 '23 Option Exercise 0.52 33,799 17,575 261,225 Aug 14 08:00 AM
Index RUT
P/E -
EPS (ttm) -0.03
Insider Own 14.57%
Shs Outstand 57.76M
Perf Week 6.10%
Market Cap 2.78B
Forward P/E 242.48
EPS next Y 0.20
Insider Trans -1.71%
Shs Float 49.52M
Perf Month -17.65%
Income -1.64M
PEG -
EPS next Q -0.16
Inst Own 85.39%
Short Float 7.23%
Perf Quarter -27.08%
Sales 493.63M
P/S 5.63
EPS this Y -1290.16%
Inst Trans 0.07%
Short Ratio 3.60
Perf Half Y -27.49%
Book/sh 8.05
P/B 5.96
EPS next Y 147.44%
ROA -0.28%
Short Interest 3.58M
Perf Year -23.17%
Cash/sh 2.00
P/C 23.96
EPS next 5Y -
ROE -0.37%
52W Range 39.90 - 71.85
Perf YTD -26.09%
Dividend Est. -
P/FCF 89.07
EPS past 5Y 32.83%
ROI -0.33%
52W High -33.22%
Beta 0.84
Dividend TTM -
Quick Ratio 2.52
Sales past 5Y 197.48%
Gross Margin 87.12%
52W Low 20.25%
ATR (14) 2.46
Dividend Ex-Date -
Current Ratio 3.09
EPS Y/Y TTM 94.57%
Oper. Margin -1.28%
RSI (14) 52.44
Volatility 5.90% 5.51%
Employees 1300
Debt/Eq 0.07
Sales Y/Y TTM 28.73%
Profit Margin -0.33%
Recom 1.45
Target Price 74.27
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 25.14%
Payout -
Rel Volume 10.22
Prev Close 47.40
Sales Surprise 0.23%
EPS Surprise -1411.48%
Sales Q/Q 22.57%
Earnings Feb 28 AMC
Avg Volume 994.22K
Price 47.98
SMA20 10.36%
SMA50 -7.51%
SMA200 -18.54%
Trades
Volume 10,160,382
Change 1.22%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-29-24 Downgrade
Piper Sandler
Overweight → Neutral
$85 → $55
Jan-23-24 Initiated
Needham
Buy
$72
Jul-19-23 Initiated
Robert W. Baird
Outperform
$79
Oct-12-22 Initiated
Jefferies
Buy
$88
Sep-29-22 Initiated
Berenberg
Buy
$85
Sep-13-22 Initiated
Truist
Hold
$87
Jun-21-22 Initiated
Piper Sandler
Overweight
$100
Mar-23-22 Resumed
BofA Securities
Buy
$105
Dec-15-20 Upgrade
Wells Fargo
Equal Weight → Overweight
$79
Nov-18-20 Initiated
BTIG Research
Buy
$92
Oct-29-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$66 → $76
Sep-28-20 Initiated
SVB Leerink
Outperform
$80
Jun-19-20 Initiated
Canaccord Genuity
Buy
Jun-16-20 Initiated
Wells Fargo
Equal Weight
$49
Jun-16-20 Initiated
Morgan Stanley
Equal-Weight
$52
Jun-16-20 Initiated
BofA/Merrill
Neutral
$56
Show Previous Ratings
Mar-25-24 06:15PM
Mar-20-24 07:01PM
Mar-14-24 10:45AM
Mar-12-24 09:00PM
04:05PM
11:30PM
Loading…
Mar-08-24 11:30PM
Mar-07-24 10:44AM
Feb-29-24 03:37PM
11:32AM
11:16AM
06:43AM
(Thomson Reuters StreetEvents)
Feb-28-24 04:37PM
04:05PM
Feb-14-24 04:05PM
Jan-23-24 07:16AM
03:13AM
Loading…
Jan-15-24 03:13AM
Jan-12-24 12:16PM
Jan-09-24 06:30AM
Jan-08-24 09:00AM
Dec-20-23 04:01PM
Dec-15-23 07:24AM
Dec-01-23 11:31AM
Nov-30-23 11:19AM
Nov-27-23 04:20PM
Nov-18-23 07:03AM
Nov-15-23 04:05PM
07:59AM
Nov-06-23 09:35AM
Nov-03-23 12:27PM
10:59AM
10:31AM
Loading…
10:31AM
08:59AM
07:01AM
Nov-02-23 07:16PM
04:01PM
11:03AM
11:02AM
(Thomson Reuters StreetEvents)
10:24AM
Nov-01-23 06:54PM
05:01PM
04:02PM
04:01PM
11:07AM
09:53AM
Oct-31-23 07:37AM
07:33AM
Oct-30-23 09:48AM
Oct-27-23 10:12AM
08:08AM
08:01AM
Oct-26-23 10:36AM
07:14AM
Oct-18-23 10:23PM
06:12AM
Oct-11-23 04:01PM
12:08PM
Oct-06-23 08:43AM
Sep-14-23 07:03PM
Aug-24-23 04:01PM
Aug-10-23 09:55AM
Aug-08-23 01:26PM
Aug-06-23 08:56AM
Aug-05-23 05:21AM
Aug-04-23 08:59AM
Aug-03-23 02:26PM
Aug-02-23 05:25PM
04:01PM
Jul-26-23 04:01PM
Jul-20-23 07:09AM
Jul-13-23 04:01PM
Jul-04-23 07:19AM
Jun-21-23 08:00PM
Jun-12-23 07:13AM
Jun-08-23 11:13AM
Jun-07-23 08:00AM
Jun-02-23 11:31AM
May-25-23 04:01PM
May-22-23 08:00AM
06:28AM
May-15-23 10:16AM
09:55AM
May-04-23 07:31AM
May-03-23 05:15PM
04:01PM
May-02-23 04:01PM
Apr-26-23 08:00PM
Apr-18-23 10:05AM
Apr-13-23 04:01PM
Apr-05-23 10:52AM
Mar-16-23 03:29PM
Mar-11-23 03:27AM
Mar-06-23 08:00AM
Mar-01-23 05:47AM
05:18AM
Feb-27-23 05:25PM
04:01PM
Feb-25-23 02:14PM
Feb-20-23 10:00AM
Feb-17-23 06:44AM
Feb-16-23 05:50AM
Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hoffman William Director Mar 18 '24 Sale 41.13 40,000 1,645,079 1,003,296 Mar 20 04:34 PM Hill, Mitch C. Chief Financial Officer Mar 12 '24 Option Exercise 0.46 6,000 2,742 189,361 Mar 14 04:31 PM Hill, Mitch C. Chief Financial Officer Mar 12 '24 Sale 41.91 6,000 251,461 183,361 Mar 14 04:31 PM Hoffman William Director Dec 15 '23 Sale 65.08 25,000 1,627,073 1,045,493 Dec 19 05:18 PM Hill, Mitch C. Chief Financial Officer Dec 12 '23 Option Exercise 0.46 6,500 2,970 176,730 Dec 14 04:35 PM Hill, Mitch C. Chief Financial Officer Dec 12 '23 Sale 62.75 6,500 407,855 170,230 Dec 14 04:35 PM Hoffman William Director Dec 04 '23 Option Exercise 0.43 103,492 44,336 1,070,493 Dec 06 05:07 PM Hykes Andrew President and CEO Nov 16 '23 Sale 59.82 37,448 2,240,277 434,817 Nov 17 07:17 PM Tu Thomas Chief Medical Officer Nov 16 '23 Sale 59.82 25,451 1,522,573 320,932 Nov 17 07:19 PM Hoffman William Director Nov 15 '23 Sale 61.24 25,000 1,531,124 967,001 Nov 17 06:27 PM Hill, Mitch C. Chief Financial Officer Nov 13 '23 Option Exercise 0.46 6,500 2,970 176,730 Nov 15 04:32 PM Hill, Mitch C. Chief Financial Officer Nov 13 '23 Sale 56.06 6,500 364,366 170,230 Nov 15 04:32 PM MILDER DONALD B Director Nov 08 '23 Buy 53.48 2,100 112,303 3,031,714 Nov 08 05:48 PM MILDER DONALD B Director Nov 07 '23 Buy 53.44 54,000 2,885,760 3,029,614 Nov 08 05:48 PM Hoffman William Director Oct 16 '23 Sale 57.28 25,000 1,432,098 992,001 Oct 18 05:39 PM Hill, Mitch C. Chief Financial Officer Oct 12 '23 Option Exercise 0.46 6,500 2,970 176,730 Oct 16 04:32 PM Hill, Mitch C. Chief Financial Officer Oct 12 '23 Sale 55.74 6,500 362,340 170,230 Oct 16 04:32 PM Hoffman William Director Sep 15 '23 Sale 66.74 25,000 1,668,503 1,023,055 Sep 19 04:38 PM Hill, Mitch C. Chief Financial Officer Sep 12 '23 Option Exercise 0.46 6,500 2,970 178,302 Sep 14 04:41 PM Hill, Mitch C. Chief Financial Officer Sep 12 '23 Sale 67.85 6,500 441,040 171,802 Sep 14 04:41 PM Hykes Andrew President and CEO Aug 16 '23 Sale 66.11 36,676 2,424,829 475,132 Aug 18 05:05 PM Tu Thomas Chief Medical Officer Aug 16 '23 Sale 66.11 24,926 1,647,980 347,997 Aug 18 05:01 PM Hoffman William Director Aug 15 '23 Sale 69.02 25,000 1,725,537 1,048,055 Aug 17 04:46 PM Hill, Mitch C. Chief Financial Officer Aug 14 '23 Option Exercise 0.46 6,500 2,970 178,302 Aug 16 04:46 PM Hill, Mitch C. Chief Financial Officer Aug 14 '23 Sale 70.47 6,500 458,053 171,802 Aug 16 04:46 PM Hoffman William Director Jul 17 '23 Sale 57.08 25,000 1,426,914 1,073,055 Jul 19 04:32 PM Hill, Mitch C. Chief Financial Officer Jul 12 '23 Option Exercise 0.46 6,500 2,970 177,982 Jul 14 04:35 PM Hill, Mitch C. Chief Financial Officer Jul 12 '23 Sale 56.24 6,500 365,540 171,482 Jul 14 04:35 PM Hoffman William Director Jun 15 '23 Sale 57.74 25,000 1,443,576 1,098,055 Jun 16 04:42 PM Hill, Mitch C. Chief Financial Officer Jun 12 '23 Option Exercise 0.46 6,500 2,970 179,554 Jun 13 05:48 PM Hill, Mitch C. Chief Financial Officer Jun 12 '23 Sale 59.24 6,500 385,088 173,054 Jun 13 05:48 PM ROOT JONATHAN D Director May 27 '23 Option Exercise 0.00 2,982 0 537,023 May 30 04:37 PM Nielsen Kirk G. Director May 27 '23 Option Exercise 0.00 2,982 0 61,479 May 30 04:35 PM MILDER DONALD B Director May 27 '23 Option Exercise 0.00 2,982 0 255,000 May 30 04:38 PM Hoffman William Director May 17 '23 Sale 69.19 41,891 2,898,438 1,120,643 May 18 08:18 PM Hykes Andrew President and CEO May 17 '23 Sale 69.19 18,760 1,298,004 513,608 May 18 08:16 PM Tu Thomas Chief Medical Officer May 17 '23 Sale 69.19 12,751 882,242 373,727 May 18 08:15 PM Hoffman William Director May 16 '23 Sale 70.87 40,006 2,835,225 1,162,534 May 18 08:18 PM Hykes Andrew President and CEO May 16 '23 Sale 70.87 17,916 1,269,707 532,368 May 18 08:16 PM Tu Thomas Chief Medical Officer May 16 '23 Sale 70.87 12,176 862,913 386,478 May 18 08:15 PM Hoffman William Director May 15 '23 Sale 70.51 25,000 1,762,860 1,202,540 May 18 08:18 PM Hill, Mitch C. Chief Financial Officer May 12 '23 Option Exercise 0.46 6,500 2,970 185,804 May 16 05:41 PM Hill, Mitch C. Chief Financial Officer May 12 '23 Sale 70.26 12,750 895,805 173,054 May 16 05:41 PM Hoffman William Director Apr 17 '23 Sale 64.67 25,000 1,616,867 1,227,540 Apr 19 04:32 PM Hill, Mitch C. Chief Financial Officer Apr 12 '23 Option Exercise 0.46 6,500 2,970 192,054 Apr 14 04:44 PM Hill, Mitch C. Chief Financial Officer Apr 12 '23 Sale 64.27 12,750 819,432 179,304 Apr 14 04:44 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite